Maravai LifeSciences (MRVI) to Post Earnings on Thursday

Maravai LifeSciences (NASDAQ:MRVI) is expected to release its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Maravai LifeSciences to announce earnings of ($0.0435) per share and revenue of $48.6730 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.06. Maravai LifeSciences had a negative net margin of 51.07% and a negative return on equity of 17.87%. The firm had revenue of $65.84 million for the quarter, compared to analyst estimates of $53.00 million. On average, analysts expect Maravai LifeSciences to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Maravai LifeSciences Price Performance

MRVI stock traded down $0.03 during trading on Tuesday, hitting $6.39. The stock had a trading volume of 383,588 shares, compared to its average volume of 2,153,534. The company has a debt-to-equity ratio of 0.72, a current ratio of 5.91 and a quick ratio of 4.96. Maravai LifeSciences has a twelve month low of $1.99 and a twelve month high of $7.44. The stock has a market capitalization of $1.65 billion, a P/E ratio of -9.01 and a beta of 0.63. The company’s 50-day moving average price is $5.84 and its two-hundred day moving average price is $4.32.

Insider Buying and Selling

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the business’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total transaction of $126,500.00. Following the transaction, the general counsel owned 360,767 shares of the company’s stock, valued at approximately $1,825,481.02. The trade was a 6.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.49% of the company’s stock.

Institutional Trading of Maravai LifeSciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. boosted its position in shares of Maravai LifeSciences by 2.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,336,680 shares of the company’s stock valued at $20,595,000 after acquiring an additional 178,445 shares during the last quarter. Mackenzie Financial Corp increased its position in Maravai LifeSciences by 1.7% during the fourth quarter. Mackenzie Financial Corp now owns 6,173,656 shares of the company’s stock worth $20,148,000 after purchasing an additional 104,355 shares during the last quarter. Geode Capital Management LLC raised its stake in Maravai LifeSciences by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 2,848,105 shares of the company’s stock worth $9,259,000 after purchasing an additional 34,447 shares during the period. State Street Corp raised its stake in Maravai LifeSciences by 1.1% during the fourth quarter. State Street Corp now owns 2,414,249 shares of the company’s stock worth $7,846,000 after purchasing an additional 27,219 shares during the period. Finally, Wellington Management Group LLP acquired a new position in Maravai LifeSciences in the 4th quarter valued at about $7,670,000. 50.25% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on MRVI shares. Weiss Ratings upgraded Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 29th. Wells Fargo & Company increased their price objective on Maravai LifeSciences from $4.50 to $5.50 and gave the company an “overweight” rating in a research note on Friday, May 8th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $6.00 price objective on shares of Maravai LifeSciences in a report on Friday, May 8th. Wall Street Zen cut shares of Maravai LifeSciences from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, UBS Group reiterated a “reduce” rating on shares of Maravai LifeSciences in a research report on Wednesday, June 3rd. Three research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $5.50.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.